DE69031563D1 - Behandlung der autoimmunen uveoretinitis in menschen - Google Patents

Behandlung der autoimmunen uveoretinitis in menschen

Info

Publication number
DE69031563D1
DE69031563D1 DE69031563T DE69031563T DE69031563D1 DE 69031563 D1 DE69031563 D1 DE 69031563D1 DE 69031563 T DE69031563 T DE 69031563T DE 69031563 T DE69031563 T DE 69031563T DE 69031563 D1 DE69031563 D1 DE 69031563D1
Authority
DE
Germany
Prior art keywords
uveoretinitis
treatment
people
autoantigen
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69031563T
Other languages
English (en)
Other versions
DE69031563T2 (de
Inventor
Howard L Weiner
David A Hafler
Robert B Nussenblatt
Alan G Palestine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Autoimmune Inc
Original Assignee
US Department of Health and Human Services
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Autoimmune Inc filed Critical US Department of Health and Human Services
Publication of DE69031563D1 publication Critical patent/DE69031563D1/de
Application granted granted Critical
Publication of DE69031563T2 publication Critical patent/DE69031563T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
DE69031563T 1989-07-14 1990-07-16 Behandlung der autoimmunen uveoretinitis in menschen Expired - Fee Related DE69031563T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37977889A 1989-07-14 1989-07-14
US55163290A 1990-07-10 1990-07-10
PCT/US1990/003989 WO1991001333A1 (en) 1989-07-14 1990-07-16 Methods of treating or preventing autoimmune uveoretinitis in mammals

Publications (2)

Publication Number Publication Date
DE69031563D1 true DE69031563D1 (de) 1997-11-13
DE69031563T2 DE69031563T2 (de) 1998-02-12

Family

ID=27008768

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69031563T Expired - Fee Related DE69031563T2 (de) 1989-07-14 1990-07-16 Behandlung der autoimmunen uveoretinitis in menschen

Country Status (15)

Country Link
US (1) US5961977A (de)
EP (1) EP0482089B1 (de)
JP (1) JP2607751B2 (de)
KR (1) KR0159046B1 (de)
AT (1) ATE158950T1 (de)
AU (1) AU670024B2 (de)
BR (1) BR9007527A (de)
CA (1) CA2063416C (de)
DE (1) DE69031563T2 (de)
DK (1) DK0482089T3 (de)
ES (1) ES2109234T3 (de)
FI (1) FI920139A0 (de)
HU (1) HUT63182A (de)
NO (1) NO920127D0 (de)
WO (1) WO1991001333A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0482089T3 (da) * 1989-07-14 1998-05-25 Autoimmune Inc Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU2001264813B2 (en) 2000-05-24 2005-12-08 The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services Methods for preventing strokes by inducing tolerance to e-selectin
WO2003079968A2 (en) * 2002-03-26 2003-10-02 Yeda Research And Development Co. Ltd Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
KR20050071565A (ko) 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
JP6671363B2 (ja) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Ｃｄ４４の単離されたポリペプチドおよびその使用
JP7108823B2 (ja) 2016-12-19 2022-07-29 パナソニックＩｐマネジメント株式会社 取付装置、電子機器、取付装置の固定方法、およびシート

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
DK0482089T3 (da) * 1989-07-14 1998-05-25 Autoimmune Inc Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
DK0506785T3 (da) * 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener

Also Published As

Publication number Publication date
ES2109234T3 (es) 1998-01-16
US5961977A (en) 1999-10-05
AU6058390A (en) 1991-02-22
CA2063416C (en) 2000-05-30
HU9200107D0 (en) 1992-04-28
EP0482089B1 (de) 1997-10-08
NO920127L (no) 1992-01-09
BR9007527A (pt) 1992-06-23
NO920127D0 (no) 1992-01-09
KR0159046B1 (ko) 1998-11-16
WO1991001333A1 (en) 1991-02-07
AU670024B2 (en) 1996-07-04
CA2063416A1 (en) 1991-01-15
JPH05501866A (ja) 1993-04-08
EP0482089A4 (en) 1993-02-17
EP0482089A1 (de) 1992-04-29
FI920139A0 (fi) 1992-01-13
HUT63182A (en) 1993-07-28
ATE158950T1 (de) 1997-10-15
DE69031563T2 (de) 1998-02-12
JP2607751B2 (ja) 1997-05-07
DK0482089T3 (da) 1998-05-25

Similar Documents

Publication Publication Date Title
DE69031563D1 (de) Behandlung der autoimmunen uveoretinitis in menschen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
ATE130762T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DE69232798D1 (de) Diagnose und behandlung von autoimmunkrankheiten
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
BR9609868A (pt) Conjugado sintético de uma proteína e uma pluralidade de epítopos para uso em medicina processos para evitar a rejeição de um xenoenxerto ou pelo menos reduzir a extensão ou taxa de rejeição para tratar uma doença e sangue removido de um doador de sangue aparelho sangue composição farmaceuticamente aceitável e uso de um conjugado
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee